Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924322 · ClinicalTrials.gov registry record · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
A Phase 2 study of Deep Venous Thrombosis, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 258
- Enrollment target
- 20
- Study locations
NCT04924322: Recruiting Phase 2 study of Deep Venous Thrombosis, sponsored by Yale University.
NCT04924322 is a Phase 2 study of Deep Venous Thrombosis that is actively recruiting participants, run by Yale University. The registered enrollment target is 258 participants, below the 438-participant average among 9 other Deep Venous Thrombosis trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04924322, a Phase 2 study of Deep Venous Thrombosis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 258 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
Primary Outcome
Thrombus in the central vein where the CVC was inserted that is diagnosed with systematic ultrasonographic surveillance.
Conditions Studied
Interventions
- DRUG Enoxaparin
Study Locations (20)
New York
- Hassenfeld Children's Hospital - New York
- New York Presbyterian Hospital - New York
- Golisano Children's Hospital - Rochester
- Maria Fareri Children's Hospital - Valhalla
Florida
- University of Florida -UF Health - Gainesville
- Johns Hopkins All Children's - St. Petersburg
Ohio
- UH Rainbow Babies & Children's Hospital - Cleveland
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Penn State Hershey Children's Hospital - Hershey
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Dell Children's Medical Canter - Austin
- UTSW Medical Center; Children's Medical Center of Dallas - Dallas
Alabama
- Children's of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What NCT04924322 shows while recruiting
NCT04924322 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, below the 438-participant average among 9 other Deep Venous Thrombosis trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Deep Venous Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Enoxaparin is the first listed.
NCT04924322 names 20 study sites across 13 states, led by New York, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04924322 about?
NCT04924322 is a clinical study titled "Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies". The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
What is the current status of trial NCT04924322?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 258 participants. The study started on 2022-05-11. Estimated completion is 2026-07-31.
What conditions does trial NCT04924322 study?
This clinical trial studies the following conditions: Deep Venous Thrombosis.
What interventions are being tested in trial NCT04924322?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT04924322?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04924322 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Deep Venous Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04924322's enrollment target sits among peer trials
258 7th of 9 higher than 3 of 9 other Deep Venous Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Deep Venous Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
COMPLETED · Phase 2
-
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
RECRUITING · NA
-
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
RECRUITING · NA
-
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
ACTIVE NOT RECRUITING
-
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
ACTIVE NOT RECRUITING · Phase 3
-
The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
- NCT05482893 · 258 participants · Phase 1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI